Health and Healthcare

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

584 Articles

Chris Lange | Jun 27, 2017 at 8:45 AM EDT

Short Sellers Run for Cover From Major Pharma

The June 15 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Jun 22, 2017 at 12:10 PM EDT

The Top 20 S&P 500 Companies Buying Back Stock in 2017

These are the top 20 stock buybacks in dollars spent during the first quarter of 2017 of all S&P 500…

Lee Jackson | Jun 12, 2017 at 10:10 AM EDT

4 Red-Hot Pharmaceutical and Biotechs Highlight Jefferies Top Stocks to Buy

A series of new reports from Jefferies focus on some of the top stocks in the pharmaceutical and biotech arenas.…

Chris Lange | Jun 12, 2017 at 8:55 AM EDT

Short Sellers Grow More Selective on Major Pharma

The May 31 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Jun 6, 2017 at 1:25 PM EDT

Celldex Therapeutics Sinks Following ASCO Results

Celldex Therapeutics was another big mover coming out of the Annual Meeting for the American Society of Clinical Oncology (ASCO).…

Chris Lange | Jun 5, 2017 at 9:45 AM EDT

7 ASCO Stocks Moving on Cancer Study News (Updated)

The Annual Meeting for the American Society of Clinical Oncology (ASCO) is currently underway in Chicago, and the health care…

Chris Lange | Jun 2, 2017 at 1:35 PM EDT

15 Companies Bracing for Big ASCO Reactions

24/7 Wall St. takes a look at the ASCO annual meeting each year and picks out the companies that could…

Lee Jackson | May 25, 2017 at 10:15 AM EDT

Big Pharma Has Big Catalysts Coming for the Rest of 2017

A new Deutsche Bank research report focuses on the big capitalization pharmaceutical stocks and the upcoming catalysts and news flow…

Chris Lange | May 25, 2017 at 9:45 AM EDT

Major Pharma Short Interest Surges

The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected…

Paul Ausick | May 15, 2017 at 11:35 AM EDT

Top Credit Suisse Pharma Picks Ahead of Catalysts

Credit Suisse provided its outlook for several large-cap pharmaceutical stocks Monday morning. The analyst has three top picks to consider.

Lee Jackson | May 12, 2017 at 8:25 AM EDT

Stock Market Looks Very Overbought: 5 Safe Stocks to Buy Now

Here are five good blue chip dividend stocks that are reasonably safe and offer good dividends, and they look good…

Trey Thoelcke | May 11, 2017 at 11:40 AM EDT

Why Big Pharma Is Not at Fault for Record Drug Spending

With prescription drug spending breaking new records almost every year now, people like to blame Big Pharma and use it…

Jon C. Ogg | May 11, 2017 at 11:00 AM EDT

Merck’s Accelerated Keytruda Lung Cancer Approval Creates 3 Moves

It is no secret that pharma and biotech shares have had to deal with at least some headwinds over the…

Chris Lange | May 10, 2017 at 9:00 AM EDT

Short Interest in Major Pharma Shrinks

The April 28 short interest data have been compared with the previous figures, and short interest moves in these selected…

Lee Jackson | May 5, 2017 at 8:20 AM EDT

JPMorgan Has 3 Top Pick Large Cap Pharmaceuticals to Buy for the Rest of 2017

JPMorgan has made the case that the best place for investors to look when considering large cap drug stocks is…

1 … 18 19 20 21 22 … 39

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

Short Sellers Run for Cover From Major Pharma

The Top 20 S&P 500 Companies Buying Back Stock in 2017

4 Red-Hot Pharmaceutical and Biotechs Highlight Jefferies Top Stocks to Buy

Short Sellers Grow More Selective on Major Pharma

Celldex Therapeutics Sinks Following ASCO Results

7 ASCO Stocks Moving on Cancer Study News (Updated)

15 Companies Bracing for Big ASCO Reactions

Big Pharma Has Big Catalysts Coming for the Rest of 2017

Major Pharma Short Interest Surges

Top Credit Suisse Pharma Picks Ahead of Catalysts

Stock Market Looks Very Overbought: 5 Safe Stocks to Buy Now

Why Big Pharma Is Not at Fault for Record Drug Spending

Merck’s Accelerated Keytruda Lung Cancer Approval Creates 3 Moves

Short Interest in Major Pharma Shrinks

JPMorgan Has 3 Top Pick Large Cap Pharmaceuticals to Buy for the Rest of 2017

Why Affluent Couples Are Draining the Higher-Earning Spouse’s 401(k) First to Avoid the Widow’s Tax Penalty

Crypto Crash Today: Why Bitcoin, Ethereum, XRP, and Solana Are All Down Double Digits

Billionaire Bill Ackman’s Pershing Square Exits Universal Music After Failed Takeover Bids, Stock Slumps 7%

Why Affluent Couples Are Draining the Higher-Earning Spouse's 401(k) First to Avoid the Widow's Tax Penalty

Middle-Class Fortysomethings Have a $427,000 Problem and a Shrinking Window to Fix It

Why Affluent Couples Are Draining the Higher-Earning Spouse’s 401(k) First to Avoid the Widow’s Tax Penalty

Crypto Crash Today: Why Bitcoin, Ethereum, XRP, and Solana Are All Down Double Digits

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

Short Sellers Run for Cover From Major Pharma

The Top 20 S&P 500 Companies Buying Back Stock in 2017

4 Red-Hot Pharmaceutical and Biotechs Highlight Jefferies Top Stocks to Buy

Short Sellers Grow More Selective on Major Pharma

Celldex Therapeutics Sinks Following ASCO Results

7 ASCO Stocks Moving on Cancer Study News (Updated)

15 Companies Bracing for Big ASCO Reactions

Big Pharma Has Big Catalysts Coming for the Rest of 2017

Major Pharma Short Interest Surges

Top Credit Suisse Pharma Picks Ahead of Catalysts

Stock Market Looks Very Overbought: 5 Safe Stocks to Buy Now

Why Big Pharma Is Not at Fault for Record Drug Spending

Merck’s Accelerated Keytruda Lung Cancer Approval Creates 3 Moves

Short Interest in Major Pharma Shrinks

JPMorgan Has 3 Top Pick Large Cap Pharmaceuticals to Buy for the Rest of 2017

Why Affluent Couples Are Draining the Higher-Earning Spouse’s 401(k) First to Avoid the Widow’s Tax Penalty

Crypto Crash Today: Why Bitcoin, Ethereum, XRP, and Solana Are All Down Double Digits

Billionaire Bill Ackman’s Pershing Square Exits Universal Music After Failed Takeover Bids, Stock Slumps 7%

Featured Reads

Why Affluent Couples Are Draining the Higher-Earning Spouse's 401(k) First to Avoid the Widow's Tax Penalty

Middle-Class Fortysomethings Have a $427,000 Problem and a Shrinking Window to Fix It